

Publications

PD Dr. med. PhD Matthias Christgen

Original Research Articles

(*corresponding author)

Raap M, Winkens W Dämmrich M, Steinmann D, Länger F, Kreipe H, **Christgen M*** (2015). High Frequency of lobular breast cancer in distant metastases to the orbit. **Cancer Med** 4:104-11.

IF: pending

Christgen M*, Geffers R, Kreipe H, Lehmann U (2013). IPH-926 lobular breast cancer cells are triple-negative but their microarray profile uncovers a luminal subtype. **Cancer Sci** 104:1726-30.

IF: 3,5

Christgen M*, Noskowicz M, Schipper E, Christgen H, Heil C, Krech T, Länger F, Kreipe H, Lehmann U (2013). Oncogenic PIK3CA mutations in lobular breast cancer progression, **Genes Chromosomes Cancer** 52:69-80.

IF: 3,8

Karch I, Schipper E, Christgen H, Kreipe H, Lehmann U, **Christgen M*** (2013). Is upregulation of BCL2 a determinant of tumor development driven by inactivation of CDH1/E-cadherin? **PloS One** 8:e73062.

IF: 3,5

Christgen M*, Noskowicz M, Heil C, Schipper E, Christgen H, Geffers R, Kreipe H, Lehmann U (2012) IPH-926 lobular breast cancer cells harbor a p53 mutant with temperature-sensitive functional activity and allow for profiling of p53-responsive genes, **Lab Invest** 92:1635-47.

IF: 4,0

Christgen M, Harbeck N, Gluz O, Nitz U, Kreipe H* (2012) Recognition and Handling of Discordant Negative Human Epidermal Growth Factor Receptor 2 Classification by Oncotype DX in Patients With Breast Cancer, **J Clin Oncol** 30:3313-4.

IF: 18,0

Knoener M, Krech T, Puls F, Lehmann U, Kreipe H, **Christgen M*** (2012) Limited value of KAI1/CD82 protein expression as a prognostic marker in human gastric cancer. **Dis Markers** 32:337-42.

IF: 2,1

Vermeulen JF, van de Ven RA, Ercan C, van der Groep P, van der Wall E, Bult P, **Christgen M**, Lehmann U, Daniel J, van Diest PJ, Derksen PW* (2012) Nuclear Kaiso expression is associated with high grade and triple-negative invasive breast cancer, **PLoS One** 7:e37864.

IF: 3,7

Krech T, Scheuerer E, Geffers R, Kreipe H, Lehmann U, and **Christgen M*** (2011). ABCB1/MDR1 contributes to the anticancer drug-resistant phenotype of IPH-926 human lobular breast cancer cells. **Cancer Lett** 315: 153-60.

IF: 4,2

Bockmeyer CL, **Christgen M**, Muller M, Fischer S, Ahrens P, Langer F, Kreipe H, and Lehmann U* (2011). MicroRNA profiles of healthy basal and luminal mammary epithelial cells are distinct and reflected in different breast cancer subtypes. **Breast Cancer Res Treat** 130:735-45.

IF: 4,4

Wolters M, Kramer MW, Becker JU, **Christgen M**, Nagele U, Imkamp F, Burchardt M, Merseburger AS, Kuczyk MA, Bach T, Gross AJ, and Herrmann TR* (2011). Tm:YAG laser en bloc mucosectomy for accurate staging of primary bladder cancer: early experience. **World J Urol** 29:429-43

IF: 2,9

Trankenschuh W, Puls F, **Christgen M**, Albat C, Heim A, Poczka J, Fleming P, Kreipe H, and Lehmann U *(2010). Frequent and distinct aberrations of DNA methylation patterns in fibrolamellar carcinoma of the liver. **PLoS One** 5:e13688

IF: 4,4

Christgen M*, Geffers R, Ballmaier M, Christgen H, Poczka J, Krech T, Kreipe H, and Lehmann U (2010). Downregulation of the fetal stem cell factor SOX17 by H33342: A mechanism responsible for differential gene expression in breast cancer side population cells. **J Biol Chem** 285:6412-6418.

IF: 5,3

Christgen M*, Christgen H, Heil C, Krech T, Langer F, Kreipe H, and Lehmann U (2009). Expression of KAI1/CD82 in distant metastases from estrogen receptor-negative breast cancer. **Cancer Science** 100:1767-1771.

IF: 3,8

Christgen M*, Bruchhardt H, Hadamitzky C, Rudolph C, Steinemann D, Gadzicki D, Hasemeier B, Romermann D, Focken T, Krech T, Ballmaier M, Schlegelberger B, Kreipe H, and Lehmann U (2009). Comprehensive genetic and functional characterization of IPH-926: a novel CDH1-null tumour cell line from human lobular breast cancer. **J Pathol** 217:620-632.

IF: 6,5

Christgen M*, Bruchhardt H, Ballmaier M, Krech T, Langer F, Kreipe H, and Lehmann U (2008). KAI1/CD82 is a novel target of estrogen receptor-mediated gene repression and downregulated in primary human breast cancer. **Int J Cancer** 123:2239-2246.

IF: 4,7

Hasemeier B, **Christgen M**, Kreipe H, and Lehmann U* (2008). Reliable microRNA profiling in routinely processed formalin-fixed paraffin-embedded breast cancer specimens using fluorescence labelled bead technology. **BMC Biotechnol** 8:90.

IF: 2,4

Lehmann U*, Hasemeier B, **Christgen M**, Muller M, Romermann D, Langer F, and Kreipe H (2008). Epigenetic inactivation of microRNA gene hsa-mir-9-1 in human breast cancer. **J Pathol** 214:17-24.

IF: 5,1

Christgen M*, Ballmaier M, Bruchhardt H, von Wasielewski R, Kreipe H, and Lehmann U (2007). Identification of a distinct side population of cancer cells in the Cal-51 human breast carcinoma cell line. **Mol Cell Biochem** 306:201-212.

IF: 1,7

Gaedcke J, Traub F, Milde S, Wilkens L, Stan A, Ostertag H, **Christgen M**, von Wasielewski R, and Kreipe HH* (2007). Predominance of the basal type and HER-2/neu type in brain metastasis from breast cancer. **Mod Pathol** 20:864-870.

IF: 4,3

Nuevemann D, **Christgen M**, Ungefroren H*, and Kalthoff H (2006). Stable expression of temperature-sensitive p53: a suitable model to study wild-type p53 function in pancreatic carcinoma cells. **Oncol Rep** 16:575-579.

IF: 1,5

Christgen M, Schniewind B, Jueschke A, Ungefroren H, and Kalthoff H* (2005). Gemcitabine-mediated apoptosis is associated with increased CD95 surface expression but is not inhibited by DN-FADD in Colo357 pancreatic cancer cells. **Cancer Lett** 227:193-200.

IF: 3,0

Schniewind B, **Christgen M**, Hauschild A, Kurdow R, Kalthoff H*, and Klomp HJ (2005). Paraneoplastic leukemoid reaction and rapid progression in a patient with malignant melanoma: establishment of KT293, a novel G-CSF-secreting melanoma cell line. **Cancer Biol Ther** 4:23-27.

IF: 0,25

Schniewind B, **Christgen M**, Kurdow R, Haye S, Kremer B, Kalthoff H*, and Ungefroren H (2004). Resistance of pancreatic cancer to gemcitabine treatment is dependent on mitochondria-mediated apoptosis. **Int J Cancer** 109:182-188.

IF: 4,4

Trauzold A, Schmiedel S, Oestern S, **Christgen M**, Westphal S, Roederm C, and Kalthoff H* (2003). Concerted deregulations of multiple apoptosis-controlling genes in pancreatic carcinoma cells. **Ann N Y Acad Sci** 1010:510-513.

IF: 0,25

Trauzold A, Schmiedel S, Roder C, Tams C, **Christgen M**, Oestern S, Arlt A, Westphal S, Kapischke M, Ungefroren H, and Kalthoff H* (2003). Multiple and synergistic deregulations of apoptosis-controlling genes in pancreatic carcinoma cells. **Br J Cancer** 89:1714-1721.

IF: 3,9

Reviews (peer-reviewed)

(*corresponding author)

Christgen M* and Derksen PWB* (2014) Lobular breast cancer: Molecular basis, mouse and cellular models. **Breast Cancer Res** 17:16.

IF: pending

Christgen M, Winkens W, Kreipe H (2014) Determination of proliferation in breast cancer by immunohistochemical detection of Ki67. **Pathologe** 35: 54-60.

IF: 1.2.

Länger F*, **Christgen M**, Kreipe H (2014) Differential diagnosis of spindle cell tumors of the breast from biopsy material. **Pathologe** 35:26-35.

IF: 1,2

Kreipe HH*, Ahrens P, **Christgen M**, Lehmann U, and Länger F (2009). [Beyond staging, typing and grading : New challenges in breast cancer pathology.]. **Pathologe** 31:54-59.

IF: folgt.

Christgen M*, and Lehmann U (2007). MDA-MB-435: The Questionable Use of a Melanoma Cell Line as a Model for Human Breast Cancer is Going On. **Cancer Biol Ther** 6:1355-1357.

IF: 2,7